All ERBB2-amplified breast cancers were HER2-positive (over-expression) clinically, with most being ER- and progesterone receptor (PR)-negative and were diagnosed evenly with early- (Group 1 and Group 2A, n = 9) and late-stage disease (n = 7). This evidence concerns the gene PGR and breast carcinoma.